HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (NASDAQ:ARDM) (the “Company”) today announced financial results for the first quarter and three months ended March 31, 2015.
Total revenue was $8.8 million for the first quarter of 2015, compared with $6.6 million in revenue for the first quarter of 2014. The increase in revenue was due to the recognition of revenue from the Grifols collaboration arrangement as the Company is being reimbursed for Pulmaquin® investigational inhaled ciprofloxacin project-related costs, as well as the revenue recognized from work being conducted under NIH grants.
Help employers find you! Check out all the jobs and post your resume.
Total revenue was $8.8 million for the first quarter of 2015, compared with $6.6 million in revenue for the first quarter of 2014. The increase in revenue was due to the recognition of revenue from the Grifols collaboration arrangement as the Company is being reimbursed for Pulmaquin® investigational inhaled ciprofloxacin project-related costs, as well as the revenue recognized from work being conducted under NIH grants.
Help employers find you! Check out all the jobs and post your resume.
